Hjem › Sklerodermi › North Carolina
Sklerodermi kliniske forsøg i North Carolina
9 studier for Sklerodermi søger deltagere på steder i North Carolina.
Byer i North Carolina
Officiel studietekst (engelsk)
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Duke University Medical Center, Durham
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Duke University, Durham
RekruttererFase 2/3
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Charlotte
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chapel Hill
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. jul. 2026 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
RekruttererFase 1
Alder 12 til 70 · Alle køn · Opdateret 22. maj 2026 · NCT06308978Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.